Search hospitals
>
Minnesota
>
Saint Paul
Minnesota Oncology Hematology PA-Woodbury
Claim this profile
Saint Paul, Minnesota 55125
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Ovarian Cancer
417 reported clinical trials
12 medical researchers
Summary
Minnesota Oncology Hematology PA-Woodbury is a medical facility located in Saint Paul, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Ovarian Cancer and other specialties. Minnesota Oncology Hematology PA-Woodbury is involved with conducting 417 clinical trials across 504 conditions. There are 12 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Area of expertise
Breast Cancer
Minnesota Oncology Hematology PA-Woodbury has run 90 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Minnesota Oncology Hematology PA-Woodbury has run 72 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
David M. King
Park Nicollet Clinic - Saint Louis Park
9 years of reported clinical research
Daniel M. Anderson
Abbott-Northwestern Hospital
7 years of reported clinical research
Yan Ji
Regions Hospital
2 years of reported clinical research
Pamala A. Pawloski
Park Nicollet Clinic - Saint Louis Park
6 years of reported clinical research
Clinical Trials running at Minnesota Oncology Hematology PA-Woodbury
Lung Cancer
Breast Cancer
Bladder Cancer
Prostate Cancer
Breast cancer
Colorectal Cancer
Cancer
Ovarian Cancer
Kidney Cancer
Esophageal cancer
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy
for Brain Metastasis from Lung Cancer
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.
Recruiting
2 awards
Phase 3
15 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting
2 awards
Phase 3
4 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Minnesota Oncology Hematology PA-Woodbury?
Minnesota Oncology Hematology PA-Woodbury is a medical facility located in Saint Paul, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Ovarian Cancer and other specialties. Minnesota Oncology Hematology PA-Woodbury is involved with conducting 417 clinical trials across 504 conditions. There are 12 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Where is Minnesota Oncology Hematology PA-Woodbury located?
**Minnesota Oncology Hematology PA-Woodbury** - **Location:** 310 Smith Ave N, Suite 100, Saint Paul, MN - **Phone:** (651) 251-5500
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance queries at Minnesota Oncology Hematology PA-Woodbury, patients can call (844) 317-4673 to connect with a social worker for support with financial assistance, transportation, and more. The Patient Benefit Representative can assist with understanding treatment costs, setting up financial plans, and navigating drug costs. Additionally, the Angel Foundation offers cash grants for qualified patients to help with non-medical financial needs during treatment.
What insurance does Minnesota Oncology Hematology PA-Woodbury accept?
Minnesota Oncology Hematology PA accepts various insurance plans, including Blue Cross and Blue Shield of Minnesota. They have been recognized by Blue Cross Blue Shield Minnesota for quality in value-based cancer care. For detailed information on accepted insurance plans, contact the healthcare provider directly or visit their website.
What awards or recognition has Minnesota Oncology Hematology PA-Woodbury received?
Minnesota Oncology Hematology PA-Woodbury, located in Saint Paul, Minnesota, is recognized by Blue Cross Blue Shield Minnesota as a Blue Distinction® Center for Cancer Care, highlighting its high-quality and cost-effective cancer treatment. It is also a member of the Metro Minnesota Community Oncology Research Consortium, offering patients access to clinical trials and cancer care research.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.